Oxford Biomedica PLC- Oxfordshire, England-based gene and cell therapy group - Says subsidiary Oxford Biomedica Solutions LLC has signed agreements with three unnamed US biotechnology firms. Under the agreements, the subsidiary will provide its full platform offering to support the new partners' pre-clinical gene therapy programmes.
Chief Executive Officer Roch Doliveux says: "Securing four new AAV customers in 2022 exceeds our original stated target of two new customers by the end of 2022. We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations.
Oxford Biomedica Solutions is a high-performing full-scope adeno-associated virus manufacturing and innovation business. Adenoviruses are a group of widely-studied viruses that are not known to cause disease and could be used for gene therapy.
Current stock price: 377.10 pence, down 1.5% on Wednesday morning in London
12-month change: down 64%
By Xindi Wei, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
Oxford Biomedica (OXB)